Glenmark Pharmaceuticals Limited

BSE: 532296 NSE: GLENMARK
Glenmark Pharmaceuticals Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24299MH1977PLC019982 Incorporated 18 November 1977 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: GLENMARK · BSE: 532296 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹16,983 Cr
▲ 27.48% YoY
Computed EBITDA · FY 2026
₹5,033.04 Cr
▲ 104.17% YoY
Net profit · FY 2026
₹1,361.95 Cr
▲ 30.06% YoY
Authorised capital
₹277 Cr
Registered with MCA
Paid-up capital
₹28.22 Cr
Issued & subscribed
Open charges
₹890 Cr
Satisfied ₹1,040 Cr
Company age
49 yrs
Est. 1977
Employees · EPFO
13,458
Latest available

About Glenmark Pharmaceuticals Limited

Data last updated: 14 July 2026

Glenmark Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 18 November 1977, the company has been in operation for over 49 years.

Registered with ROC Mumbai under CIN L24299MH1977PLC019982. Listed on BSE: 532296 and NSE: GLENMARK.

Capital: an authorised share capital of ₹277 Cr and a paid-up capital of ₹28.22 Cr. Formerly known as Glenmark Pharmaceuticals Private Limited. It is led by directors including Sona Saira Ramasastry and Glenn Mario Saldanha.

Last AGM: 26 September 2025. Financial statements filed for year ended 31 March 2025. Office: B – 2Mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, India – 400026.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹16,983 Cr, a growth of 27.48% compared to the previous year. The net worth stands at ₹10,512 Cr (up 18.79% YoY). Total assets are valued at ₹19,908 Cr (up 24.04% YoY).

The company has a workforce of approximately 13,458 employees as per the latest available data. Its group structure includes 1 subsidiary.

The company is associated with 1 brand - Glenmark Pharmaceuticals. As per MCA filings, the company has open charges of ₹890 Cr and satisfied charges of ₹1,040 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glenmarkpharma.com.

Company Details of Glenmark Pharmaceuticals Limited
CIN L24299MH1977PLC019982
Registration Number 019982
Incorporation Date 18 November 1977
ROC Mumbai
Listing Status Listed (BSE: 532296, NSE: GLENMARK)
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Glenn Mario Saldanha Managing Director Cherylann Maria Pinto Whole-Time Director Anurag Mantri Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    glenmarkpharma.com
  • Social Media
  • Registered Address
    B – 2Mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, India – 400026
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers
Company report
Glenmark Pharmaceuticals Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Glenmark Pharmaceuticals Limited report

Financials, compliance, directors, charges, ownership and filings for Glenmark Pharmaceuticals Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited operates one associated brand: Glenmark Pharmaceuticals. These brands represent Glenmark Pharmaceuticals Limited's diversified market presence and brand portfolio.

Brand Description Website
Glenmark Pharmaceuticals
R&D company focused on manufacturing generic drugs for multiple therapeutic areas glenmarkpharma.com

Competitors & Alternatives of Glenmark Pharmaceuticals Limited

Brands and companies operating in the same space as Glenmark Pharmaceuticals Limited include Merck, Roivant Sciences, Amgen and 7 more.

Competitor Description Location Founded
Merck Merck Pharmaceutical products are manufactured and marketed worldwide. Kenilworth, United Kingdom, United Kingdom 1891
Roivant Sciences Roivant Sciences Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. New York, United States, United States 2014
Amgen Amgen Developer of pharmaceutical products for treating multiple diseases Thousand Oaks, United States, United States 1980
AbbVie AbbVie Biopharmaceutical research and drug development are conducted globally by AbbVie. Chicago, United States, United States 2012
Lilly Lilly Traditional pharmaceutical medicines are developed for multiple health fields. United States 1876
Bausch & Lomb Bausch & Lomb Ophthalmic pharmaceuticals and instruments are developed for eye care. Bridgewater, United States, United States 1853
Roche Roche Pharmaceuticals and diagnostics kits are developed for various diseases. Basel, Switzerland, Switzerland 1896
Novo Nordisk Novo Nordisk Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. Bagsvaerd, Denmark, Denmark 1923
Sanofi Sanofi Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. Paris, France, France 1973
GSK GSK Developer of pharmaceuticals and vaccines for various therapeutic areas Brentford, United Kingdom, United Kingdom -

Business Activity of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Glenmark Pharmaceuticals Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited is audited by Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited is currently managed by 9 directors, with 18 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Sona Saira Ramasastry Director 01 Apr 2019 7 Years 4 Months Current
Glenn Mario Saldanha
Also directs: Glenmark Healthcare Limited, Glenmark Consumer Care Limited
Managing Director 12 Oct 1998 27 Years 10 Months Current
Blanche Saldanha Elizabeth Director 14 Aug 2009 17 Years 0 Months Current
Cherylann Maria Pinto
Also directs: Glenmark Healthcare Limited
Whole-Time Director 16 May 2007 19 Years 3 Months Current
Dipankar Bhattacharjee Director 14 Aug 2020 6 Years 0 Months Current
Vijayalakshmi Iyer
Also directs: Icici Bank Limited, Computer Age Management Services Limited, Cg Power And Industrial Solutions Limited and 5 more
Director 10 Feb 2023 3 Years 6 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Glenmark Pharmaceuticals Limited FY 2026 filings available

Glenmark Pharmaceuticals Limited reported revenue of ₹16,983 Cr (up 27.48% YoY) for FY 2026.

Revenue · FY 2026
₹16,983 Cr ▲ 27.48%
Profit · FY 2026
₹1,361.95 Cr ▲ 30.06%
Computed EBITDA · FY 2026
₹5,033.04 Cr ▲ 104.17%
Revenue₹ Cr · Consolidated010,00020,000FY 2020: ₹10,641 Cr10,641FY 2020FY 2021: ₹10,944 Cr · +2.8% YoY10,944+2.8%FY 2021FY 2022: ₹12,305 Cr · +12.4% YoY12,305+12.4%FY 2022FY 2023: ₹12,990 Cr · +5.6% YoY12,990+5.6%FY 2023FY 2024: ₹11,813 Cr · -9.1% YoY11,813-9.1%FY 2024FY 2025: ₹13,322 Cr · +12.8% YoY13,322+12.8%FY 2025FY 2026: ₹16,983 Cr · +27.5% YoY16,983+27.5%FY 2026
Net Profit₹ Cr · Consolidated-1,500-1,000-50005001,0001,500FY 2020: ₹776 Cr776FY 2020FY 2021: ₹970 Cr · +25% YoY970+25%FY 2021FY 2022: ₹994 Cr · +2.4% YoY994+2.4%FY 2022FY 2023: ₹377 Cr · -62% YoY377-62%FY 2023FY 2024: ₹1,434 Cr (loss) · -479.8% YoY-1,434FY 2024FY 2025: ₹1,047 Cr · +173% YoY1,047+173%FY 2025FY 2026: ₹1,362 Cr · +30.1% YoY1,362+30.1%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year02,5005,0007,500Q1'25: ₹3,244 Cr · -4.6% YoY3,244-4.6%Q1'25Q2'25: ₹3,434 Cr · +7.1% YoY3,434+7.1%Q2'25Q3'25: ₹3,388 Cr · +35.1% YoY3,388+35.1%Q3'25Q4'25: ₹3,256 Cr · +6.3% YoY3,256+6.3%Q4'25Q1'26: ₹3,264 Cr · +0.6% YoY3,264+0.6%Q1'26Q2'26: ₹6,047 Cr · +76.1% YoY6,047+76.1%Q2'26Q3'26: ₹3,901 Cr · +15.1% YoY3,901+15.1%Q3'26Q4'26: ₹3,771 Cr · +15.8% YoY3,771+15.8%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹16,983 Cr ₹13,322 Cr ₹11,813 Cr ₹12,990 Cr ₹12,305 Cr ₹10,944 Cr ₹10,641 Cr
Other Income ₹460.62 Cr ₹113.72 Cr ₹839.99 Cr ₹316.79 Cr ₹166.67 Cr ₹50.22 Cr ₹159.6 Cr
Total Income ₹17,443 Cr ₹13,435 Cr ₹12,653 Cr ₹13,307 Cr ₹12,472 Cr ₹10,994 Cr ₹10,801 Cr
Cost of Materials Consumed ₹2,961.46 Cr ₹3,001.27 Cr ₹3,157.82 Cr ₹3,593.79 Cr ₹3,278.76 Cr ₹3,137.81 Cr ₹2,541.47 Cr
Purchases of Stock-in-Trade ₹2,396.64 Cr ₹1,566 Cr ₹1,451.17 Cr ₹1,268.26 Cr ₹1,117.67 Cr ₹750.27 Cr ₹1,029.08 Cr
Changes in Inventories -₹610.64 Cr -₹213.93 Cr -₹195.62 Cr -₹325.09 Cr -₹11.14 Cr -₹189.25 Cr ₹128.08 Cr
Employee Benefit Expense ₹3,577.85 Cr ₹3,022.06 Cr ₹2,868.14 Cr ₹2,780.96 Cr ₹2,447.42 Cr ₹2,343.71 Cr ₹2,254.78 Cr
Finance Costs ₹208.73 Cr ₹207.07 Cr ₹515.97 Cr ₹349.58 Cr ₹298.1 Cr ₹353.11 Cr ₹377.32 Cr
Depreciation & Amortisation ₹573.48 Cr ₹486.01 Cr ₹581.91 Cr ₹611.27 Cr ₹486.72 Cr ₹443.55 Cr ₹417.17 Cr
Other Expenses ₹4,084.78 Cr ₹3,594.96 Cr ₹3,336.25 Cr ₹3,393.83 Cr ₹3,151.9 Cr ₹2,817.02 Cr ₹2,989.47 Cr
Total Expenses ₹13,192 Cr ₹11,663 Cr ₹11,716 Cr ₹11,673 Cr ₹10,769 Cr ₹9,656.22 Cr ₹9,737.37 Cr
Profit Before Exceptional Items & Tax ₹4,250.83 Cr ₹1,772.03 Cr ₹937.45 Cr ₹1,634.31 Cr ₹1,702.16 Cr ₹1,337.93 Cr ₹1,063.2 Cr
Exceptional Items -₹2,266.08 Cr -₹372.82 Cr -₹900.96 Cr -₹765.85 Cr -₹260.91 Cr ₹44.55 Cr ₹32.88 Cr
Profit Before Tax ₹1,984.75 Cr ₹1,399.21 Cr ₹36.5 Cr ₹868.45 Cr ₹1,441.25 Cr ₹1,382.48 Cr ₹1,096.08 Cr
Total Tax Expense ₹622.79 Cr ₹352.07 Cr ₹1,867.35 Cr ₹491.05 Cr ₹447.6 Cr ₹412.39 Cr ₹320.11 Cr
Net Profit ₹1,361.95 Cr ₹1,047.14 Cr -₹1,433.52 Cr ₹377.4 Cr ₹993.65 Cr ₹970.09 Cr ₹775.97 Cr
  attributable to Owners ₹10.1 Lakh ₹1,047.1 Cr -₹1,501.67 Cr ₹0 ₹941.71 Cr ₹0 ₹0
  attributable to NCI ₹1,361.85 Cr ₹4.5 Lakh ₹68.15 Cr ₹0 ₹51.94 Cr ₹0 ₹0
Other Comprehensive Income ₹414.36 Cr ₹64.2 Cr -₹65.55 Cr ₹153.73 Cr ₹76.71 Cr ₹86.68 Cr -₹245.72 Cr
Total Comprehensive Income ₹1,776.31 Cr ₹1,111.34 Cr -₹1,499.08 Cr ₹531.13 Cr ₹1,070.36 Cr ₹1,056.77 Cr ₹530.26 Cr
EBITDA (computed) ₹5,033.04 Cr ₹2,465.1 Cr ₹2,035.33 Cr ₹2,595.16 Cr ₹2,486.97 Cr ₹2,134.6 Cr ₹1,857.68 Cr
Basic EPS ₹48.26 ₹37.11 ₹-67.30 ₹10.53 ₹33.37 ₹34.38 ₹27.50
Diluted EPS ₹48.24 ₹37.10 ₹-67.30 ₹10.53 ₹33.37 ₹34.38 ₹27.50
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹19,908 Cr ₹16,050 Cr ₹14,359 Cr ₹19,372 Cr
Non-current Assets ₹8,608.17 Cr ₹6,754.09 Cr ₹6,930.54 Cr ₹9,497.96 Cr
Current Assets ₹11,300 Cr ₹9,295.47 Cr ₹7,428.08 Cr ₹9,873.72 Cr
Property, Plant & Equipment ₹3,889.57 Cr ₹3,319.37 Cr ₹3,118.15 Cr ₹3,904.16 Cr
Inventories ₹3,430.78 Cr ₹3,028.53 Cr ₹2,513.05 Cr ₹2,977.79 Cr
Trade Receivables ₹4,963.35 Cr ₹3,341.95 Cr ₹1,858.41 Cr ₹4,098.61 Cr
Cash & Equivalents ₹1,174.71 Cr ₹1,675.71 Cr ₹1,658.27 Cr ₹1,443.03 Cr
Equity (Net Worth) ₹10,512 Cr ₹8,849.07 Cr ₹7,847.55 Cr ₹9,839.26 Cr
Equity Share Capital ₹28.22 Cr ₹28.22 Cr ₹28.22 Cr ₹28.22 Cr
Borrowings (Non-current) ₹0 ₹512.7 Cr ₹0 ₹3,852.14 Cr
Borrowings (Current) ₹0 ₹1,681.5 Cr ₹990.6 Cr ₹495.58 Cr
Total Debt (computed) ₹0 ₹2,194.2 Cr ₹990.6 Cr ₹4,347.72 Cr
Current Liabilities ₹6,376.43 Cr ₹5,967.02 Cr ₹5,818.59 Cr ₹5,045.53 Cr
Total Liabilities ₹9,396.08 Cr ₹7,200.48 Cr ₹6,511.08 Cr ₹9,532.42 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹3,445.03 Cr -₹827.6 Cr -₹265.44 Cr ₹625.39 Cr ₹1,108.65 Cr
Investing Cash Flow -₹1,283.23 Cr ₹2.09 Cr ₹4,369.14 Cr -₹528.49 Cr -₹333.28 Cr
Financing Cash Flow -₹2,708.75 Cr ₹787.05 Cr -₹3,906.13 Cr -₹77.46 Cr -₹520.49 Cr
Capital Expenditure ₹1,357.71 Cr ₹749.57 Cr ₹898.38 Cr ₹607.76 Cr ₹790.12 Cr
Free Cash Flow (computed) ₹2,087.32 Cr -₹1,577.16 Cr -₹1,163.82 Cr ₹17.63 Cr ₹318.54 Cr
Dividends Paid ₹141.03 Cr ₹70.44 Cr ₹117.75 Cr ₹136.61 Cr ₹92.7 Cr
Net Change in Cash -₹501 Cr ₹17.44 Cr ₹215.24 Cr ₹32.5 Cr ₹272.43 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹3,770.59 Cr ₹3,900.62 Cr ₹6,046.87 Cr ₹3,264.44 Cr ₹3,256.21 Cr ₹3,387.55 Cr ₹3,433.8 Cr ₹3,244.19 Cr ₹3,062.95 Cr ₹2,506.7 Cr ₹3,207.38 Cr ₹3,401.6 Cr
Other Income ₹189.08 Cr ₹44.47 Cr ₹200.63 Cr ₹26.44 Cr ₹11.69 Cr ₹31.13 Cr ₹39.42 Cr ₹31.49 Cr ₹773.17 Cr ₹45.41 Cr ₹1.7 Cr ₹20.87 Cr
Total Income ₹3,959.67 Cr ₹3,945.08 Cr ₹6,247.5 Cr ₹3,290.88 Cr ₹3,267.89 Cr ₹3,418.68 Cr ₹3,473.21 Cr ₹3,275.68 Cr ₹3,836.12 Cr ₹2,552.11 Cr ₹3,209.07 Cr ₹3,422.48 Cr
Cost of Materials Consumed ₹731.2 Cr ₹775.3 Cr ₹722.5 Cr ₹732.47 Cr ₹794.78 Cr ₹746.37 Cr ₹774.36 Cr ₹685.77 Cr ₹754.31 Cr ₹657.51 Cr ₹915.75 Cr ₹932.13 Cr
Purchases of Stock-in-Trade ₹446.29 Cr ₹748.56 Cr ₹620.45 Cr ₹581.34 Cr ₹344.74 Cr ₹418.15 Cr ₹443.08 Cr ₹360.03 Cr ₹210.8 Cr ₹413.11 Cr ₹408.83 Cr ₹406.93 Cr
Changes in Inventories -₹5.21 Cr -₹228.76 Cr -₹78.44 Cr -₹298.23 Cr -₹50.57 Cr -₹80.28 Cr -₹147.36 Cr ₹64.28 Cr ₹30.42 Cr -₹38.35 Cr -₹126.8 Cr -₹111.06 Cr
Employee Benefit Expense ₹887.44 Cr ₹841.4 Cr ₹1,086.26 Cr ₹762.75 Cr ₹736.57 Cr ₹788.49 Cr ₹786.57 Cr ₹710.44 Cr ₹700.96 Cr ₹753.04 Cr ₹732.88 Cr ₹729.41 Cr
Finance Costs ₹42.6 Cr ₹41.43 Cr ₹66.46 Cr ₹58.23 Cr ₹66.71 Cr ₹52.29 Cr ₹48.48 Cr ₹39.58 Cr ₹148.56 Cr ₹134.34 Cr ₹121.46 Cr ₹112 Cr
Depreciation & Amortisation ₹147.91 Cr ₹154.45 Cr ₹141.2 Cr ₹129.93 Cr ₹125.21 Cr ₹122.74 Cr ₹120.28 Cr ₹117.79 Cr ₹151.34 Cr ₹147.08 Cr ₹141.45 Cr ₹154.65 Cr
Other Expenses ₹948.27 Cr ₹894.37 Cr ₹1,336.56 Cr ₹905.59 Cr ₹869.66 Cr ₹914.6 Cr ₹975.24 Cr ₹835.45 Cr ₹862.13 Cr ₹930.05 Cr ₹814.43 Cr ₹812.99 Cr
Total Expenses ₹3,198.5 Cr ₹3,226.74 Cr ₹3,894.98 Cr ₹2,872.07 Cr ₹2,887.1 Cr ₹2,962.35 Cr ₹3,000.64 Cr ₹2,813.34 Cr ₹2,858.51 Cr ₹2,996.77 Cr ₹3,008.01 Cr ₹3,037.05 Cr
Profit Before Exceptional Items & Tax ₹761.17 Cr ₹718.34 Cr ₹2,352.52 Cr ₹418.81 Cr ₹380.79 Cr ₹456.33 Cr ₹472.57 Cr ₹462.33 Cr ₹977.61 Cr -₹444.66 Cr ₹201.07 Cr ₹385.43 Cr
Exceptional Items -₹373.4 Cr -₹184.34 Cr -₹1,385.12 Cr -₹323.23 Cr -₹372.82 Cr ₹0 ₹0 ₹0 -₹446.78 Cr -₹76.72 Cr -₹325.42 Cr -₹52.02 Cr
Profit Before Tax ₹387.77 Cr ₹534 Cr ₹967.4 Cr ₹95.58 Cr ₹7.97 Cr ₹456.33 Cr ₹472.57 Cr ₹462.33 Cr ₹530.83 Cr -₹521.38 Cr -₹124.36 Cr ₹333.41 Cr
Total Tax Expense ₹86.45 Cr ₹130.77 Cr ₹356.97 Cr ₹48.61 Cr ₹3.59 Cr ₹108.3 Cr ₹118.09 Cr ₹122.1 Cr ₹1,769.47 Cr -₹71.8 Cr ₹55.95 Cr ₹160.28 Cr
Net Profit ₹301.32 Cr ₹403.23 Cr ₹610.43 Cr ₹46.97 Cr ₹4.38 Cr ₹348.03 Cr ₹354.49 Cr ₹340.24 Cr -₹1,214.27 Cr -₹330.82 Cr -₹63.55 Cr ₹173.13 Cr
  attributable to Owners -₹9.5 Lakh ₹403.21 Cr ₹610.35 Cr ₹46.87 Cr ₹4.65 Cr ₹0 ₹0 - -₹1,218.28 Cr -₹351.38 Cr -₹81.95 Cr ₹23.19 Cr
  attributable to NCI ₹301.41 Cr ₹1.5 Lakh ₹7.9 Lakh ₹10.2 Lakh -₹26.6 Lakh ₹0 ₹0 - ₹4.01 Cr ₹20.56 Cr ₹20.38 Cr ₹149.93 Cr
Other Comprehensive Income ₹188.62 Cr ₹19.95 Cr ₹104.48 Cr ₹101.31 Cr ₹257.58 Cr -₹176.47 Cr -₹22.4 Cr ₹5.49 Cr ₹75.88 Cr ₹4.74 Cr -₹88.03 Cr -₹56.16 Cr
Total Comprehensive Income ₹489.94 Cr ₹423.18 Cr ₹714.91 Cr ₹148.29 Cr ₹261.96 Cr ₹171.56 Cr ₹332.08 Cr ₹345.73 Cr -₹1,138.39 Cr -₹326.07 Cr -₹151.58 Cr ₹116.97 Cr
EBITDA (computed) ₹951.68 Cr ₹914.21 Cr ₹2,560.18 Cr ₹606.96 Cr ₹572.71 Cr ₹631.36 Cr ₹641.33 Cr ₹619.71 Cr ₹1,277.51 Cr -₹163.24 Cr ₹463.98 Cr ₹652.09 Cr
Basic EPS ₹10.68 ₹14.29 ₹21.63 ₹1.66 ₹0.16 ₹12.33 ₹12.55 ₹12.06 ₹-44.04 ₹-16.66 ₹-7.11 ₹5.31
Diluted EPS ₹10.68 ₹14.28 ₹21.62 ₹1.66 ₹0.16 ₹12.33 ₹12.55 ₹12.06 ₹-44.04 ₹-16.66 ₹-7.11 ₹5.31
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹8,440.1 Cr ₹9,226.41 Cr ₹7,891.12 Cr ₹8,220.66 Cr ₹8,141.58 Cr ₹7,567.93 Cr ₹6,712.63 Cr
Other Income ₹772.02 Cr ₹356.37 Cr ₹1,168.02 Cr ₹985.94 Cr ₹614.63 Cr ₹396.24 Cr ₹606.79 Cr
Total Income ₹9,212.12 Cr ₹9,582.78 Cr ₹9,059.14 Cr ₹9,206.6 Cr ₹8,756.21 Cr ₹7,964.17 Cr ₹7,319.42 Cr
Cost of Materials Consumed ₹2,775.58 Cr ₹2,781.45 Cr ₹2,990.41 Cr ₹3,035.88 Cr ₹2,993.04 Cr ₹2,678.26 Cr ₹2,251.98 Cr
Purchases of Stock-in-Trade ₹408.8 Cr ₹373.21 Cr ₹322.78 Cr ₹391.19 Cr ₹481.62 Cr ₹315.96 Cr ₹365.24 Cr
Changes in Inventories -₹105.42 Cr ₹44.48 Cr -₹103.07 Cr -₹31.37 Cr -₹16.13 Cr ₹5.24 Cr ₹48.77 Cr
Employee Benefit Expense ₹1,790.41 Cr ₹1,603.5 Cr ₹1,434.78 Cr ₹1,346.51 Cr ₹1,193.2 Cr ₹1,107.4 Cr ₹1,072.33 Cr
Finance Costs ₹78.75 Cr ₹48.73 Cr ₹277.11 Cr ₹206.82 Cr ₹236.04 Cr ₹265.9 Cr ₹256.39 Cr
Depreciation & Amortisation ₹235.89 Cr ₹218.63 Cr ₹202.16 Cr ₹184.15 Cr ₹159.7 Cr ₹150.82 Cr ₹138.54 Cr
Other Expenses ₹2,493.34 Cr ₹2,179.6 Cr ₹2,004.56 Cr ₹2,005.68 Cr ₹1,801.64 Cr ₹1,570.74 Cr ₹1,670.08 Cr
Total Expenses ₹7,677.34 Cr ₹7,249.59 Cr ₹7,128.73 Cr ₹7,138.86 Cr ₹6,849.1 Cr ₹6,094.31 Cr ₹5,803.33 Cr
Profit Before Exceptional Items & Tax ₹1,534.79 Cr ₹2,333.18 Cr ₹1,930.42 Cr ₹2,067.74 Cr ₹1,907.11 Cr ₹1,869.87 Cr ₹1,516.09 Cr
Exceptional Items -₹1,800.86 Cr -₹179.17 Cr ₹5,070.33 Cr -₹495.87 Cr ₹430.33 Cr ₹73.89 Cr ₹18.55 Cr
Profit Before Tax -₹266.07 Cr ₹2,154.02 Cr ₹7,000.75 Cr ₹1,571.87 Cr ₹2,337.45 Cr ₹1,943.76 Cr ₹1,534.64 Cr
Total Tax Expense -₹65.27 Cr ₹543.67 Cr ₹1,833.46 Cr ₹363.11 Cr ₹339.66 Cr ₹294.31 Cr ₹180.1 Cr
Net Profit -₹200.8 Cr ₹1,610.35 Cr ₹5,167.29 Cr ₹1,208.77 Cr ₹1,997.79 Cr ₹1,649.45 Cr ₹1,354.55 Cr
Other Comprehensive Income -₹16.96 Cr -₹6.47 Cr -₹4.76 Cr ₹63.2 Lakh ₹1.61 Cr ₹2.48 Cr -₹5.42 Cr
Total Comprehensive Income -₹217.76 Cr ₹1,603.88 Cr ₹5,162.53 Cr ₹1,209.4 Cr ₹1,999.39 Cr ₹1,651.93 Cr ₹1,349.13 Cr
EBITDA (computed) ₹1,849.42 Cr ₹2,600.55 Cr ₹2,409.69 Cr ₹2,458.71 Cr ₹2,302.85 Cr ₹2,286.58 Cr ₹1,911.02 Cr
Basic EPS ₹-7.12 ₹57.07 ₹183.13 ₹42.84 ₹70.80 ₹58.46 ₹48.00
Diluted EPS ₹-7.11 ₹57.07 ₹183.12 ₹42.84 ₹70.80 ₹58.46 ₹48.00
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹29,485 Cr ₹28,033 Cr ₹27,414 Cr ₹24,586 Cr
Non-current Assets ₹23,390 Cr ₹23,256 Cr ₹22,733 Cr ₹20,201 Cr
Current Assets ₹6,095.1 Cr ₹4,777.67 Cr ₹4,681.47 Cr ₹4,385.18 Cr
Property, Plant & Equipment ₹1,747.66 Cr ₹1,660.81 Cr ₹1,538.58 Cr ₹1,488.67 Cr
Inventories ₹1,288.06 Cr ₹1,369.31 Cr ₹1,142.69 Cr ₹1,090.21 Cr
Trade Receivables ₹3,305.59 Cr ₹2,550.16 Cr ₹2,484.47 Cr ₹2,505.66 Cr
Cash & Equivalents ₹291.83 Cr ₹131.45 Cr ₹127.96 Cr ₹92.7 Cr
Equity (Net Worth) ₹24,150 Cr ₹24,504 Cr ₹22,971 Cr ₹17,877 Cr
Equity Share Capital ₹28.22 Cr ₹28.22 Cr ₹28.22 Cr ₹28.22 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹2,660.82 Cr
Borrowings (Current) ₹0 ₹698.82 Cr ₹657.24 Cr ₹495.58 Cr
Total Debt (computed) ₹0 ₹698.82 Cr ₹657.24 Cr ₹3,156.4 Cr
Current Liabilities ₹3,669.03 Cr ₹3,245.91 Cr ₹4,289.39 Cr ₹3,641.77 Cr
Total Liabilities ₹5,334.85 Cr ₹3,529.33 Cr ₹4,443.77 Cr ₹6,708.46 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹543.3 Cr ₹588.8 Cr -₹495.45 Cr ₹1,474.06 Cr ₹1,216.07 Cr
Investing Cash Flow ₹569.23 Cr -₹489.52 Cr ₹3,197.19 Cr -₹431.47 Cr -₹896.92 Cr
Financing Cash Flow -₹952.13 Cr -₹95.41 Cr -₹2,666.45 Cr -₹978.5 Cr -₹305.12 Cr
Capital Expenditure ₹0 ₹340.95 Cr ₹195.11 Cr ₹189.62 Cr ₹163.35 Cr
Free Cash Flow (computed) ₹543.3 Cr ₹247.84 Cr -₹690.56 Cr ₹1,284.44 Cr ₹1,052.72 Cr
Dividends Paid ₹141.03 Cr ₹70.44 Cr ₹70.45 Cr ₹70.43 Cr ₹70.62 Cr
Net Change in Cash ₹160.38 Cr ₹3.49 Cr ₹35.27 Cr ₹64.05 Cr ₹13.93 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹2,146.58 Cr ₹2,359.94 Cr ₹1,538.66 Cr ₹2,394.93 Cr ₹2,009.49 Cr ₹2,251.28 Cr ₹2,636.1 Cr ₹2,329.54 Cr ₹2,148.22 Cr ₹1,365.1 Cr ₹2,233.42 Cr ₹2,144.38 Cr
Other Income ₹307.88 Cr ₹109.06 Cr ₹285.76 Cr ₹69.34 Cr ₹88.45 Cr ₹129.19 Cr ₹83.08 Cr ₹55.65 Cr ₹786.27 Cr ₹258.82 Cr ₹46.22 Cr ₹49.36 Cr
Total Income ₹2,454.45 Cr ₹2,468.99 Cr ₹1,824.42 Cr ₹2,464.26 Cr ₹2,097.95 Cr ₹2,380.47 Cr ₹2,719.18 Cr ₹2,385.19 Cr ₹2,934.49 Cr ₹1,623.91 Cr ₹2,279.63 Cr ₹2,193.75 Cr
Cost of Materials Consumed ₹720.92 Cr ₹709.6 Cr ₹667.82 Cr ₹677.24 Cr ₹696.01 Cr ₹714.76 Cr ₹722.57 Cr ₹648.11 Cr ₹685.45 Cr ₹701.17 Cr ₹807.03 Cr ₹796.76 Cr
Purchases of Stock-in-Trade ₹113.5 Cr ₹104.66 Cr ₹91.31 Cr ₹99.33 Cr ₹91.48 Cr ₹89.09 Cr ₹103.65 Cr ₹88.99 Cr ₹81.66 Cr ₹77.72 Cr ₹81.23 Cr ₹82.17 Cr
Changes in Inventories -₹92.9 Lakh ₹56.77 Cr -₹102.85 Cr -₹58.41 Cr -₹1.38 Cr -₹18.95 Cr ₹7.88 Cr ₹56.92 Cr -₹2.12 Cr -₹83.94 Cr ₹6.08 Cr -₹23.08 Cr
Employee Benefit Expense ₹461.35 Cr ₹466.95 Cr ₹453.68 Cr ₹408.44 Cr ₹382.7 Cr ₹427.98 Cr ₹408.42 Cr ₹384.4 Cr ₹337.75 Cr ₹379.56 Cr ₹383 Cr ₹334.47 Cr
Finance Costs ₹17.91 Cr ₹21.98 Cr ₹23.4 Cr ₹15.46 Cr ₹13.13 Cr ₹8.46 Cr ₹11.8 Cr ₹15.35 Cr ₹83.39 Cr ₹73.6 Cr ₹58.19 Cr ₹61.93 Cr
Depreciation & Amortisation ₹60.13 Cr ₹59.18 Cr ₹58.93 Cr ₹57.64 Cr ₹55.53 Cr ₹55.16 Cr ₹54.85 Cr ₹53.09 Cr ₹52.4 Cr ₹51.16 Cr ₹49.85 Cr ₹48.75 Cr
Other Expenses ₹820.21 Cr ₹526.26 Cr ₹606.7 Cr ₹540.17 Cr ₹500.15 Cr ₹544.48 Cr ₹614.96 Cr ₹520.01 Cr ₹548.04 Cr ₹474.85 Cr ₹485.23 Cr ₹469.08 Cr
Total Expenses ₹2,193.09 Cr ₹1,945.39 Cr ₹1,798.99 Cr ₹1,739.87 Cr ₹1,737.62 Cr ₹1,820.98 Cr ₹1,924.12 Cr ₹1,766.87 Cr ₹1,786.56 Cr ₹1,674.13 Cr ₹1,870.6 Cr ₹1,770.07 Cr
Profit Before Exceptional Items & Tax ₹261.36 Cr ₹523.6 Cr ₹25.43 Cr ₹724.4 Cr ₹360.32 Cr ₹559.49 Cr ₹795.06 Cr ₹618.31 Cr ₹1,147.93 Cr -₹50.22 Cr ₹409.04 Cr ₹423.67 Cr
Exceptional Items -₹368.76 Cr -₹177.07 Cr -₹931.79 Cr -₹323.23 Cr -₹179.17 Cr ₹0 ₹0 ₹0 ₹5,146.91 Cr -₹25.28 Cr -₹19.67 Cr -₹31.63 Cr
Profit Before Tax -₹107.4 Cr ₹346.53 Cr -₹906.37 Cr ₹401.17 Cr ₹181.16 Cr ₹559.49 Cr ₹795.06 Cr ₹618.31 Cr ₹6,294.85 Cr -₹75.5 Cr ₹389.37 Cr ₹392.04 Cr
Total Tax Expense -₹33.5 Cr ₹64.46 Cr -₹167.18 Cr ₹70.94 Cr ₹33.4 Cr ₹145.69 Cr ₹200 Cr ₹164.58 Cr ₹1,681.15 Cr -₹55.09 Cr ₹87.01 Cr ₹120.39 Cr
Net Profit -₹73.9 Cr ₹282.07 Cr -₹739.19 Cr ₹330.23 Cr ₹147.76 Cr ₹413.8 Cr ₹595.06 Cr ₹453.73 Cr ₹4,613.7 Cr -₹20.41 Cr ₹302.35 Cr ₹271.66 Cr
Other Comprehensive Income -₹3.75 Cr ₹1.94 Cr -₹14.62 Cr -₹53.4 Lakh -₹3 Cr -₹53 Lakh -₹2.12 Cr -₹81.5 Lakh -₹3 Lakh -₹65.6 Lakh -₹3.55 Cr -₹52.7 Lakh
Total Comprehensive Income -₹77.65 Cr ₹284.01 Cr -₹753.81 Cr ₹329.69 Cr ₹144.76 Cr ₹413.27 Cr ₹592.94 Cr ₹452.92 Cr ₹4,613.67 Cr -₹21.07 Cr ₹298.81 Cr ₹271.13 Cr
EBITDA (computed) ₹339.41 Cr ₹604.76 Cr ₹107.76 Cr ₹797.49 Cr ₹428.98 Cr ₹623.12 Cr ₹861.7 Cr ₹686.75 Cr ₹1,283.72 Cr ₹74.55 Cr ₹517.07 Cr ₹534.36 Cr
Basic EPS ₹-2.62 ₹10.00 ₹-26.19 ₹11.70 ₹5.24 ₹14.66 ₹21.09 ₹16.08 ₹163.50 ₹-0.72 ₹10.72 ₹9.63
Diluted EPS ₹-2.62 ₹9.99 ₹-26.19 ₹11.70 ₹5.24 ₹14.66 ₹21.09 ₹16.08 ₹163.50 ₹-0.72 ₹10.72 ₹9.63
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Glenmark Pharmaceuticals Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Glenmark Pharmaceuticals Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 46.65%, foreign institutional investors hold 20.34%, domestic institutional investors hold 19.29%, retail and other public shareholders hold 13.68% of Glenmark Pharmaceuticals Limited. The company had 196,105 shareholders on record.

Promoters: 46.65%DII (Domestic Institutional): 19.29%FII (Foreign Institutional): 20.34%Retail & Others: 13.68%
Mar 2026
QUARTER
46.65% Promoters
19.29% DII (Domestic Institutional)
20.34% FII (Foreign Institutional)
13.68% Retail & Others
Promoter holding - history
Now 46.65% · Mar 2026High 46.65% · Sep 2021Low 46.47% · Dec 2015
45%45.8%46.5%47.3%48%Dec 2015Jun 2018Mar 2021Sep 2023Mar 2026Dec 2015: 46.47%Mar 2016: 46.48%Jun 2016: 46.48%Sep 2016: 46.49%Dec 2016: 46.49%Mar 2017: 46.50%Jun 2017: 46.53%Sep 2017: 46.53%Dec 2017: 46.54%Mar 2018: 46.54%Jun 2018: 46.54%Sep 2018: 46.54%Dec 2018: 46.54%Mar 2019: 46.54%Jun 2019: 46.58%Sep 2019: 46.58%Dec 2019: 46.59%Mar 2020: 46.62%Sep 2020: 46.63%Dec 2020: 46.63%Mar 2021: 46.63%Jun 2021: 46.63%Sep 2021: 46.65%Dec 2021: 46.65%Mar 2022: 46.65%Jun 2022: 46.65%Sep 2022: 46.65%Dec 2022: 46.65%Mar 2023: 46.65%Jun 2023: 46.65%Sep 2023: 46.65%Dec 2023: 46.65%Mar 2024: 46.64%Jun 2024: 46.65%Sep 2024: 46.65%Dec 2024: 46.65%Mar 2025: 46.65%Jun 2025: 46.65%Sep 2025: 46.65%Dec 2025: 46.65%Mar 2026: 46.65%46.65%46.47%46.65%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters46.65%46.65%46.65%46.65%46.65%46.65%
Public53.35%53.35%53.35%53.35%53.35%53.35%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters46.65%46.65%46.64%46.65%46.65%46.63%46.62%46.54%46.54%46.50%46.48%
Public53.35%53.35%53.36%53.35%53.35%53.37%53.38%53.46%53.46%53.50%53.52%
Promoter change (YoY, %pts)+0.00+0.01-0.01+0.00+0.02+0.01+0.08+0.00+0.04+0.02-

Board & Governance of Glenmark Pharmaceuticals Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Glenmark Pharmaceuticals Limited has 9 directors - 5 independent and 3 executive. The board is chaired by GLENN MARIO SALDANHA.

DirectorPositionOn board sinceListed boards
BLANCHE ELIZABETH SALDANHA Non-Executive - Non Independent Director 2009-08-14 1
GLENN MARIO SALDANHA Executive Director · CEO-MD · Chairperson 1998-10-12 1
CHERYLANN MARIA PINTO Executive Director 2007-05-16 1
SAIRA RAMASASTRY Non-Executive - Independent Director 2019-04-01 1
DIPANKAR BHATTACHARJEE Non-Executive - Independent Director 2020-08-14 1
VIJAYALAKSHMI RAJARAM IYER Non-Executive - Independent Director 2023-02-10 4
PRADEEP KUMAR SINHA Non-Executive - Independent Director 2025-02-14 2
ANURAG MANTRI Executive Director 2025-05-27 1
PATRICIA ANDREWS Non-Executive - Independent Director 2025-08-14 1
Board Committees
CommitteeMembers
Audit Committee VIJAYALAKSHMI RAJARAM IYER (Chairperson), SAIRA RAMASASTRY, DIPANKAR BHATTACHARJEE
Nomination and remuneration committee DIPANKAR BHATTACHARJEE (Chairperson), GLENN MARIO SALDANHA, VIJAYALAKSHMI RAJARAM IYER
Stakeholders Relationship Committee SAIRA RAMASASTRY (Chairperson), CHERYLANN MARIA PINTO, PATRICIA ANDREWS
Risk Management Committee DIPANKAR BHATTACHARJEE (Chairperson), GLENN MARIO SALDANHA, ANURAG MANTRI, PATRICIA ANDREWS
Corporate Social Responsibility Committee CHERYLANN MARIA PINTO (Chairperson), VIJAYALAKSHMI RAJARAM IYER, PRADEEP KUMAR SINHA

Group Structure of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has 1 subsidiary company. This group structure data is as of FY 2024. The corporate group structure reflects Glenmark Pharmaceuticals Limited's business expansion strategy and organizational complexity.

1
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Glenmark Healthcare Limited U21001MH2023PLC402796 -

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Glenmark Pharmaceuticals Limited

Open charges
₹890 Cr
Satisfied charges
₹1,040 Cr
Breakdown by lending institutions
Bank of India₹890.00 Cr
Latest charge details
DateLenderAmountStatus
21 May 1985 Bank of India ₹890 Cr Open
29 Jul 2009 Bank of India ₹60 Cr Satisfied
18 Jun 2009 Axis Bank Limited ₹75 Cr Satisfied
16 Jan 2009 Central Bank of India ₹150 Cr Satisfied
09 Jun 2008 Bank of India ₹170 Cr Satisfied

Total charge records: 14 View all charges

Employees and EPFO Compliance at Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has a workforce of 13,458 employees as of Mar 08, 2025.

Employee count
13,458
Active EPFO establishments
2
Employee growth
8.3%
Premium access

Employee and EPFO history for Glenmark Pharmaceuticals Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Glenmark Pharmaceuticals Limited

Premium access

GST registrations and filing compliance for Glenmark Pharmaceuticals Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Glenmark Pharmaceuticals Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Glenmark Pharmaceuticals Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Glenmark Pharmaceuticals Limited

Premium access

MSME payment history for Glenmark Pharmaceuticals Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Glenmark Pharmaceuticals Limited

Premium access

Corporate group structure for Glenmark Pharmaceuticals Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Glenmark Pharmaceuticals Limited

Premium access

MCA filings and documents for Glenmark Pharmaceuticals Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Glenmark Pharmaceuticals Limited

Directors
12 Jun 2026
Rashmi Khandelwal was appointed as a Company Secretary on 12 Jun 2026 & has been associated with this company since 2 months 10 days.
Activity
26 Sep 2025
Glenmark Pharmaceuticals Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Directors
14 Aug 2025
Patricia Susan Andrews was appointed as a Director on 14 Aug 2025 & has been associated with this company since 1 year 6 days.
Directors
06 Jun 2025
Anurag Mantri was appointed as a Cfo on 06 Jun 2025 & has been associated with this company since 1 year 2 months.
Directors
27 May 2025
Anurag Mantri was appointed as a Whole-time director on 27 May 2025 & has been associated with this company since 1 year 2 months.
Activity
31 Mar 2025
Glenmark Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.

Recent News on Glenmark Pharmaceuticals Limited

Focus on Paytm, Zaggle Prepaid, DLF, UltraTech, Patanjali
17 Apr 2025 · Thehindubusinessline
Stocks that will see action today: April 15, 2025
15 Apr 2025 · Thehindubusinessline
Stocks that will see action today: 11 April , 2025
11 Apr 2025 · Thehindubusinessline
Stocks that will see action today: March 21, 2025
21 Mar 2025 · Thehindubusinessline

Frequently Asked Questions about Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 18 November 1977 (49+ years old) and is registered under CIN L24299MH1977PLC019982. Listed on BSE: 532296 and NSE: GLENMARK. The company has 13,458 employees.

Glenmark Pharmaceuticals Limited reported revenue of ₹16,983 Cr for FY 2026 (up 27.48% YoY) based on consolidated NSE filings.

The current directors of Glenmark Pharmaceuticals Limited are:

The primary industry of Glenmark Pharmaceuticals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Glenmark Pharmaceuticals Limited is listed on both BSE (code: 532296) and NSE (symbol: GLENMARK).

Glenmark Pharmaceuticals Limited can be reached at the registered office: B – 2Mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, India – 400026, or through the website glenmarkpharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available